Miss Holly Evans

Journal articles

• Fan R, Satilmis H, Vandewalle N, Verheye E, Vlummens P, Maes A, Muylaert C, De Bruyne E, Menu E, Evans H , Chantry A et al (2023) Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma. Journal for ImmunoTherapy of Cancer, 11(1), e005319-e005319.
• Fan R, Satilmis H, Vandewalle N, De Bruyne E, Menu E, Chantry AD, Evans H, Törngren M, Eriksson H, Breckpot K , Maes K et al (2021) Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects By Inhibiting c-Myc Expression in Vitro and In Vivo. Blood, 138(Supplement 1), 1594-1594.
• Zhang D, De Veirman K, Fan R, Jian Q, Zhang Y, Lei L, Evans H, Wang Y, Lei L, Wang B , Williamson RA et al (2020) ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation. Stem Cell Research & Therapy, 11(1).
• Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, Evans HR, Gartland A & Erler JT (2019) Correction: LOXL2-Mediated Matrix Remodeling in Metastasis and Mammary Gland Involution. Cancer Research, 79(19), 5123-5123.
• Green AC, Lath D, Hudson K, Walkley B, Down JM, Owen R, Evans HR, Paton‐Hough J, Reilly GC, Lawson MA & Chantry AD (2019) TGFβ inhibition stimulates collagen maturation to enhance bone repair and fracture resistance in a murine myeloma model. Journal of Bone and Mineral Research. View this article in WRRO
• Leitch VD, Brassill MJ, Rahman S, Butterfield NC, Ma P, Logan JG, Boyde A, Evans H, Croucher PI, Batterham RL , Williams GR et al (2019) PYY is a negative regulator of bone mass and strength. Bone, 127, 427-435.
• Paton-Hough J, Tazzyman S, Evans H, Lath D, Down JM, Green AC, Snowden JA, Chantry AD & Lawson MA (2018) Preventing and repairing myeloma bone disease by combining conventional antiresorptive treatment with a bone anabolic agent in murine models. Journal of Bone and Mineral Research. View this article in WRRO
• Lath DL, Buckle CH, Evans HR, Fisher M, Down JM, Lawson MA & Chantry AD (2018) ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.. PLoS One, 13(6). View this article in WRRO
• Lawson MA, Ebetino FH, Mazur A, Chantry AD, Paton-Hough J, Evans HR, Lath D, Tsoumpra MK, Lundy MW, Dobson RLM , Quijano M et al (2017) The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1‐Fluoro‐2‐(Imidazo‐[1,2‐α]Pyridin‐3‐yl)‐Ethyl‐Bisphosphonate). Journal of Bone and Mineral Research, 32(9), 1860-1869. View this article in WRRO
• Leitch VD, Di Cosmo C, Liao X-H, O’Boy S, Galliford TM, Evans H, Croucher PI, Boyde A, Dumitrescu A, Weiss RE , Refetoff S et al (2017) An Essential Physiological Role for MCT8 in Bone in Male Mice. Endocrinology, 158(9), 3055-3066. View this article in WRRO
• Evans HR, Karmakharm T, Lawson MA, Walker RE, Harris W, Fellows C, Huggins ID, Richmond P & Chantry AD (2016) Osteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods. Bone, 83, 9-16.
• Kassen D, Lath D, Lach A, Evans H, Chantry A, Rabin N, Croucher P & Yong KL (2016) Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model. British Journal of Haematology, 172(1), 64-79.
• Cox TR, Rumney RMH, Schoof EM, Perryman L, Høye AM, Agrawal A, Bird D, Latif NA, Forrest H, Evans HR , Huggins ID et al (2015) The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature, 522(7554), 106-110. View this article in WRRO
• Bassett JHD, Boyde A, Zikmund T, Evans H, Croucher PI, Zhu X, Park JW, Cheng S-Y & Williams GR (2014) Thyroid hormone receptor α mutation causes a severe and thyroxine-resistant skeletal dysplasia in female mice.. Endocrinology, 155(9), 3699-3712.
• Bentley L, Esapa CT, Nesbit MA, Head RA, Evans H, Lath D, Scudamore CL, Hough TA, Podrini C, Hannan FM , Fraser WD et al (2014) An N-ethyl-N-nitrosourea induced corticotropin-releasing hormone promoter mutation provides a mouse model for endogenous glucocorticoid excess.. Endocrinology, 155(3), 908-922.
• Xu S, De Veirman K, Evans H, Santini GC, Vande Broek I, Leleu X, De Becker A, Van Camp B, Croucher P, Vanderkerken K & Van Riet I (2013) Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo. Acta Pharmacologica Sinica, 34(5), 699-709.
• Loh NY, Bentley L, Dimke H, Verkaart S, Tammaro P, Gorvin CM, Stechman MJ, Ahmad BN, Hannan FM, Piret SE , Evans H et al (2013) Autosomal dominant hypercalciuria in a mouse model due to a mutation of the epithelial calcium channel, TRPV5.. PLoS One, 8(1), e55412. View this article in WRRO
• Esapa CT, Head RA, Jeyabalan J, Evans H, Hough TA, Cheeseman MT, McNally EG, Carr AJ, Thomas GP, Brown MA , Croucher PI et al (2012) A mouse with an N-ethyl-N-nitrosourea (ENU) induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis. PLoS ONE, 7(8). View this article in WRRO
• Bassett JHD, Gogakos A, White JK, Evans H, Jacques RM, van der Spek AH, Sanger Mouse Genetics Project , Ramirez-Solis R, Ryder E, Sunter D , Boyde A et al (2012) Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strength.. PLoS Genet, 8(8), e1002858. View this article in WRRO
• Bassett JHD, Logan JG, Boyde A, Cheung MS, Evans H, Croucher P, Sun X-Y, Xu S, Murata Y & Williams GR (2012) Mice lacking the calcineurin inhibitor Rcan2 have an isolated defect of osteoblast function.. Endocrinology, 153(7), 3537-3548.
• Chantry AD, Heath D, Mulivor AW, Pearsall S, Baud'huin M, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML , Key ML et al (2012) Erratum: Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. Journal of Bone and Mineral Research, 27(9), 2036-2037.
• Xu S, De Becker A, De Veirman K, Hu J, Xu D, Menu E, Vande Broek I, Camp BV, Vanderkerken K, Van Riet I , Evans H et al (2012) Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. Leukemia.
• Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, Evans HR, Gartland A & Erler JT (2011) LOXL2-mediated matrix remodeling in metastasis and mammary gland involution.. Cancer Res, 71(5), 1561-1572.
• Chantry AD, Heath D, Mulivor AW, Pearsall S, Baud'huin M, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML , Key ML et al (2010) Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo.. J Bone Miner Res, 25(12), 2633-2646.
• Bassett JHD, Boyde A, Howell PGT, Bassett RH, Galliford TM, Archanco M, Evans H, Lawson MA, Croucher P, Germain DLS , Galton VA et al (2010) Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts. P NATL ACAD SCI USA, 107(16), 7604-7609.
• Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD, Evans HR, Snowden JA, Stover DR, Vanderkerken K & Croucher PI (2009) Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.. J Bone Miner Res, 24(3), 425-436.
• Heath DJ, Chantry AD, Buckle C, Coulton L, Shaughnessy JD, Evans H, Stover DR, Vanderkerken K & Croucher PI (2008) Inhibiting Dickkopf-1 (Dkk-1) prevents the development of osteolytic bone disease in multiple myeloma. CALCIFIED TISSUE INT, 83(1), 6-6.
• Chantry A, Heath D, Coulton L, Gallagher O, Evans H, Vanderkerken K, Seehra JS & Croucher PI (2008) RAP-011, a soluble activin receptor type IIA IgG-Fc fusion protein, is a novel bone anabolic agent that prevents bone disease in multiple myeloma. CLIN EXP METASTAS, 25, 64-64.
• Kirby J, Hewamadduma CAA, Hartley JA, Nixon HC, Evans H, Wadhwa RR, Kershaw C, Ince PG & Shaw PJ (2007) Mutations in VAPB are not associated with sporadic ALS.. Neurology, 68(22), 1951-1953.
• Lawson M, Chantry A, Paton-Hough J, Evans H, Lath D, Tsoumpra M, Lundy M, Dobson R, Quijano M, Kwaasi A , Dunford J et al () The pharmacological profile of a novel highly potent bisphosphonate, OX14 (1-fluoro-2-(imidazo-[1,2 alpha]pyridin-3-yl)ethyl-bisphosphonate), with reduced bone affinity, which is as effective as zoledronate in the treatment of myeloma bone disease in JJN3-NOD/SCID-[gamma] mice. Bone Abstracts.
• Lawson MA, Paton-Hough JM, Evans HR, Walker RE, Harris W, Ratnabalan D, Snowden JA & Chantry AD () NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease. PLOS ONE, 10(3), e0119546-e0119546. View this article in WRRO
• Esapa CT, Bassett JHD, Evans H, Croucher PI, Williams GR & Thakker RV () Bone Mineral Content and Density.
• Esapa C, Hough T, Evans HR, Testori S, Head R, Crane E, Chan C, Bassett J, Tylzanowski P & McNally E () A mouse model for spondyloepiphyseal dysplasia congenita with secondary osteoarthritis due to a Col2a1 mutation. J Bone Miner Res..

Conference proceedings papers

• Zhu Y, Green AC, Guo L, Evans HR & Mihaylova L (2020) Machine Learning Approaches for Cancer Bone Segmentation from Micro Computed Tomography Images. 2020 IEEE 23rd International Conference on Information Fusion (FUSION), 6 July 2020 - 9 July 2020. View this article in WRRO
• Arnold ND, Pickworth JA, Carvalho JA, Braithwaite AT, Iremonger J, West L, Casbolt HL, Renshall LJ, Germaschewski V, McCourt M , Evans HR et al (2017) Development of a Novel Human Anti-OPG Antibody That Attenuates Experimental Pulmonary Arterial Hypertension. CIRCULATION, Vol. 136
• Chantry AD, Baud'huin M, Coulton L, Gallagher O, Evans H, Lath D, Seehra J, Pearsall S, De Raeve H, Vanderkerken K & Croucher PI (2011) Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the development of osteolytic bone disease in the 5T2MM murine model of myeloma. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 153 (pp 7-7)
• Evans HR, Ab Latif N, Cox TR, Bird D, Lang G, Erler JT & Gartland A (2011) Tumour-secreted lox mediates osteolytic bone metastases prior to metastatic tumour cell colonisation. BONE, Vol. 48(1) (pp S21-S21)
• Williams A, Lawson M, Bos T, Amani E, Hough J, Evans H, Lath D, Gallagher O, Coulton L, Vanderkerken K & Croucher P (2010) Imaging and quantitation of multiple myeloma in calvariae. BONE, Vol. 47 (pp S328-S328)
• Abdul N, Stoop W, Koopman W, Djerbi M, Chantry AD, Evans H, Vanderkerken K & Croucher PI (2009) Inhibiting glycogen synthase kinase-3 (GSK-3) prevents the development of myeloma bone disease. BONE, Vol. 44 (pp S53-S54)
• Chantry A, Coulton L, Gallagher O, Evans H, Seehra J, Pearsall S, De Raeve H, Vanderkerken K & Croucher R (2009) Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the formation of osteolytic bone disease in the 5T2MM murine model of myeloma. BONE, Vol. 44 (pp S55-S55)
• Orriss IR, Evans HR, Gartland A & Arnett TR (2008) Microct analysis of P2Y1 and P2Y2 receptor knockout mice demonstrates significant changes in bone phenotype. CALCIFIED TISSUE INT, Vol. 83(1) (pp 2-3)
• Orriss I, Evans H, Arnett T & Gartland A (2008) MicroCT analysis of P2Y1 and P2Y2 receptor knockout mice demonstrates significant changes in bone phenotype. PURINERG SIGNAL, Vol. 4 (pp S176-S176)
• Chantry A, Heath D, Coutton L, Evans H, Abdul N, Seehra J, Vanderkerken K & Croucher P (2008) A soluble activin type II receptor prevents the development of myeloma bone disease. CANCER TREATMENT REVIEWS, Vol. 34 (pp S56-S57)
• Heath D, Chantry A, Buckle C, Coulton L, Shaughnessy J, Evans H, Stover D, Vanderkerken K & Croucher P (2008) Inhibiting dickkopf-1 (Dkk-1) prevents the development of osteolytic bone disease in multiple myeloma. CANCER TREATMENT REVIEWS, Vol. 34 (pp S52-S52)
• Chantry AD, Heath D, Coulton L, Gallagher O, Evans H, Seehra J, Vanderkerken K & Croucher PI (2007) A soluble activin type II receptor prevents myeloma bone disease. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1118-1118)
• Chantry A, Heath D, Coulton L, Gallagher O, Evans H, Seehra J, Vanderkerken K & Croucher PI (2007) A soluble activin type II receptor prevents myeloma bone disease. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol. 92(6) (pp 133-133)